Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Capnopharm Announces Asset Purchase of Capnomed as PIPAC™ Shows Superiority Over IV Chemotherapy in 1st Randomised Data presented at ASCO 2022

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Capnopharm GmbH today announced it has entered into an asset purchase agreement to acquire all operating assets from Capnomed GmbH.

Founded in 2015, Capnomed has played an essential role in developing Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC™). PIPAC™ is a new, minimally-invasive method of treating peritoneal cancer delivering novel therapies to the entire affected tissue with precision and safety. Capnomed successfully introduced the medical device Capnopen™, the gold standard of laparoscopic nebulizers. Capnomed created a new market for intraperitoneal drug delivery, and developed PIPAC™’s ecosystem through academic collaborations, support for translational research and clinical studies, and unrestricted educational grants to peer-reviewed journals and scientific societies.

“One million patients develop peritoneal cancer globally every year. There is no truly effective therapy. Capnopharm’s vision is to change this and to shape the future of peritoneal cancer care”, said Ranjita Sahoo, PhD, Capnopharm’s Chief Scientific Officer. First randomized data presented at ASCO 2022 showed superiority of PIPACTM™ with cisplatin and doxorubicin over systemic intravenous chemotherapy in platin-resistant ovarian cancer.”

He added, “Compared to intravenous chemotherapy, PIPACTM™ had better response rate and improved quality of life with minimal morbidity. There are at least 40 further registered clinical trials evaluating PIPACTM™’s safety and efficacy in various indications, including a collaborative PIPACTM™ trial with the Capnopen™ in the USA. “Capnopharm will increasingly focus on next-generation strategies to overcome the challenges of existing therapies of peritoneal cancer. This will include repurposing and reformulating generic drugs, exploring nanotechnology, immunotherapy, cytolytic virotherapy and mRNA as new-era therapy platforms “, adds Dr. Sahoo.

“PIPACTM™ will ultimately benefit to the patients. The acquisition of Capnomed’s assets will generate unique synergies at the crossroads of medical need, engineering, and pharmaceutical sciences. This acquisition will further diversify our business, create operational synergies, facilitate market access and enhance Capnopharm’s value” said Prof. Marc A. Reymond, MD MBA, Capnopharm’s CEO.


References

[1] https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.5524

[1] https://www.clinicaltrials.gov/ct2/results?cond=&term=pipac&cntry=&state=&city=&dist=

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine